Table 1

Hypermethylation of MGMT promoter in primary tumors

Primary tumors
Brain tumors55/166 (33%)
 Gliomas54/140 (38%)
 Nongliomas1/26 (3%)
Colon cancer14/36 (38%)
Lung cancer10/41 (24%)
 NSCLC10/34 (29%)
 SCLC0/7
Head and neck carcinoma6/21 (28%)
Lymphomas15/61 (25%)
Breast cancer0/36
Ovarian cancer0/23
Endometrial cancer0/17
Leukemias2/31 (6%)
Pancreatic carcinoma2/18 (11%)
Melanoma2/18 (11%)
Renal carcinoma1/12 (8%)
Bladder carcinoma2/44 (4%)